LTI-03 Reached Patients With Pulmonary Fibrosis. The Biomarker Signal Is Promising, Not Proof.
The first peer-reviewed patient study of inhaled LTI-03 found acceptable 14-day tolerability and shifts in fibrosis-linked biomarkers. It did not test whether patients breathe better or decline more slowly.
For years, LTI-03 has lived in the most frustrating part of peptide research: convincing biology, human lung-tissue experiments, and no published evidence from people with the disease it is meant to treat. That changed on July 31, 2026, when researchers published the first randomized patient study of the inhaled peptide in Nature Communications.
The short version is encouraging but narrow. Twenty-four people with idiopathic pulmonary fibrosis, or IPF, inhaled LTI-03 or placebo for 14 days. The treatment did not produce severe drug-related safety problems or signs of airway obstruction. Several fibrosis-linked biomarkers moved in the hoped-for direction. What the study did not show is just as important: it did not establish that LTI-03 preserves lung function, reverses scarring, improves symptoms, or extends life.
That distinction matters because IPF is relentless. Scar tissue thickens the delicate architecture around the air sacs, making oxygen transfer harder and breathing progressively more difficult. Approved antifibrotic drugs can slow decline for some patients, but they do not reliably stop the disease. A locally delivered peptide that protects alveolar cells while quieting fibrotic signaling would be genuinely useful. The question is whether a two-week molecular signal can become a durable clinical benefit.
The study was designed to answer a safety question
This was a Phase 1b, randomized, double-blind, placebo-controlled dose-escalation trial registered as NCT05954988. Participants had been diagnosed with IPF within three years of screening. None reported using nintedanib, pirfenidone, or another investigational antifibrotic within two months of screening or during the study.
Nine participants received 5 milligrams of LTI-03 per day, nine received 10 milligrams per day, and six received placebo. The dry powder was self-administered by inhaler twice daily for 14 days. Within each sequential dose cohort, assignment was three-to-one in favor of active treatment. The primary endpoint was the incidence of treatment-emergent adverse events. Lung function and disease biomarkers were secondary or exploratory assessments, not proof-of-efficacy endpoints.
All 24 participants completed the study. Any treatment-emergent adverse event was reported in 66.7% of the 5-milligram group, 77.8% of the 10-milligram group, and 50% of the placebo group. Those percentages look high until you inspect the events: most were mild, and cough was the main one. Cough occurred in three of nine people at the lower dose, five of nine at the higher dose, and two of six on placebo. Two treatment-related cough events were Grade 2 and resolved the same day.
There were no deaths, no adverse events that caused treatment discontinuation, and no Grade 3 or higher events. One participant had a Grade 2 fever after bronchoscopy and stayed overnight for observation; investigators judged it unrelated to LTI-03. Spirometry and symptom reports did not show airway obstruction, worsening chronic cough, or clinically meaningful short-term changes in FEV1 or forced vital capacity, usually shortened to FVC.
The most interesting result came from the airways, not the spirometer
Researchers sampled deep bronchial brushings and tested a panel of biomarkers chosen from earlier LTI-03 experiments. Compared with placebo, both doses significantly reduced interleukin-11 and thymic stromal lymphopoietin. At 10 milligrams per day, the study also found reductions in COL1A1, CXCL7, and galectin-7. These molecules touch different parts of the IPF process, including collagen production, inflammatory signaling, and epithelial stress.
The exact statistics deserve to be visible. For interleukin-11, the reported p values were 0.0406 at 5 milligrams and 0.044 at 10 milligrams. For thymic stromal lymphopoietin they were 0.0256 and 0.0128. At the higher dose, COL1A1 and CXCL7 each had a p value of 0.0248, while galectin-7 had a p value of 0.0332. Other measured biomarkers did not change significantly.
That pattern is compatible with local target engagement: the inhaled peptide reached diseased airways and appears to have altered some of the pathways it was designed to influence. Plasma concentrations were below the assay’s quantification limit after dosing in every participant, while LTI-03 was measurable in bronchoalveolar lavage fluid from five treated participants. The researchers interpret that as evidence of lung-focused delivery with little systemic exposure. It is a reasonable interpretation, although the lavage measurements were inconsistent and affected by low solubility, collection timing, and sample volume.
Why a seven-amino-acid peptide could matter
LTI-03 is a synthetic fragment of the scaffolding domain of caveolin-1, a protein involved in cell-membrane organization and signaling. Caveolin-1 expression is reduced in several cell types in IPF lungs. Without enough of that regulatory influence, signals that encourage fibroblast activation, extracellular-matrix deposition, and abnormal repair may run unchecked.
The proposed strategy is not to replace the whole protein. LTI-03 uses seven natural L-amino acids from its active region as a compact signaling tool. Earlier work in animal models, fibroblasts, alveolar organoids, and precision-cut slices from human IPF lungs suggested two complementary effects: suppressing profibrotic activity and helping alveolar epithelial cells survive. A 2025 iScience study found dose-dependent reductions in collagen staining and several profibrotic transcripts in ex vivo IPF lung slices.
The inhaled formulation is central to the idea. A dry powder can put the peptide close to the cells involved in disease while reducing whole-body exposure. That is attractive for a chronic lung condition, but local delivery brings its own challenge: an inhaled product has to avoid irritating already vulnerable airways. The Phase 1b cough data are therefore not a footnote. They are part of the engineering problem the program must solve.
Here is where the optimism needs brakes
Twenty-four participants, including only six on placebo, cannot establish a reliable safety profile for uncommon harms. Fourteen days cannot tell us what repeated inhalation does over months or years. The study enrolled recently diagnosed participants who were not taking standard antifibrotic therapy around the trial, so it also does not answer how LTI-03 behaves alongside the treatment many patients currently receive.
The biomarker analysis was exploratory. Researchers tested multiple markers and used one-tailed Mann-Whitney tests because they had directional hypotheses that the markers would fall. That approach can be appropriate for an early target-engagement study, but it produces a weaker claim than a prospectively powered clinical endpoint with correction for multiple comparisons. A lower collagen-related signal in bronchial cells is not the same thing as less fibrosis on imaging, slower loss of FVC, easier breathing, or longer survival.
The paper was fully funded by Rein Therapeutics. Several authors were company employees, held stock or options, consulted for the company, or received institutional support. Industry involvement is normal in drug development and does not erase a randomized, peer-reviewed result. It does mean the next layer of evidence should be larger, outcomes-focused, and independently scrutinized.
The Phase 2 trial is the real test
LTI-03 has already moved into the Phase 2 RENEW study, NCT06968845. The registry describes a blinded, randomized trial of approximately 120 people with IPF, split among low-dose LTI-03, high-dose LTI-03, and matched placebo groups. The major efficacy question is change in FVC, a practical measure of how much air a person can forcibly exhale after a full breath.
That design moves the program from “can patients inhale it for two weeks?” toward “does it alter the course of lung-function decline?” It also gives researchers more time and more participants to characterize cough, respiratory tolerability, and other adverse events. Even a positive FVC result would need confirmation and context: duration, magnitude, background antifibrotic use, imaging, symptoms, exacerbations, and discontinuation rates all matter.
A negative Phase 2 result would not make the Phase 1b biomarker findings false. It would show that molecular movement was not enough to create a useful clinical effect under the tested conditions. That is common in fibrosis research, where elegant mechanisms often collide with established tissue damage and a highly variable disease course.
The Oria take
LTI-03 has crossed an important boundary. It is no longer only a peptide that looked antifibrotic in mice and donated lung tissue. A small randomized study now suggests that people with IPF can inhale it for 14 days without an obvious severe safety signal, and that the treatment reaches the lung while changing several relevant biomarkers.
The honest headline stops there. There is no human evidence yet that LTI-03 reverses lung scarring or helps patients breathe better. There is not enough exposure to judge long-term safety. The most useful result of this study is that it gives the Phase 2 program a rational dose, a tolerability baseline, and evidence that the mechanism may be active in the intended tissue.
For patients and families following the pipeline, RENEW is the milestone to watch. Until it reports, LTI-03 belongs in clinical research, not in a self-directed peptide protocol. It is investigational, unavailable as an approved IPF treatment, and not interchangeable with products sold online under similar names.
Sources
Evidence grade: B- for short-term human safety and target engagement; D for clinical efficacy. The study was randomized, blinded, placebo-controlled, and peer reviewed, but it included only 24 participants, lasted 14 days, and relied on exploratory biomarkers. It did not demonstrate better lung function, symptoms, imaging, hospitalization, or survival.
Medical disclaimer: This article is for education only and is not medical advice. LTI-03 is investigational and is not approved to treat idiopathic pulmonary fibrosis. Do not buy, compound, or use research peptides based on this report. People with IPF should discuss approved antifibrotic therapy, supportive care, and legitimate clinical-trial options with an interstitial-lung-disease specialist. Oria exists to make emerging peptide evidence easier to evaluate, not to replace clinical care.
Build Your Personalised Protocol
Turn your research into a personalised supplementation protocol with the BioStack Generator.